NASDAQ:ANGO AngioDynamics (ANGO) Stock Price, News & Analysis $6.74 +0.02 (+0.30%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About AngioDynamics Stock (NASDAQ:ANGO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AngioDynamics alerts:Sign Up Key Stats Today's Range$6.69▼$6.8850-Day Range$5.88▼$7.7852-Week Range$5.26▼$8.25Volume500,986 shsAverage Volume527,276 shsMarket Capitalization$273.87 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company OverviewAngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.Read More… Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late AngioDynamics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks95th Percentile Overall ScoreANGO MarketRank™: AngioDynamics scored higher than 95% of companies evaluated by MarketBeat, and ranked 72nd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAngioDynamics has only been the subject of 2 research reports in the past 90 days.Read more about AngioDynamics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AngioDynamics are expected to grow in the coming year, from ($0.41) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AngioDynamics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.03% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 16.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.99 Percentage of Shares Shorted3.03% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 16.89%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.08 News SentimentAngioDynamics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AngioDynamics this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for ANGO on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows3 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $135,847.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AngioDynamics' insider trading history. Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANGO Stock News HeadlinesAngioDynamics Shareholder Approvals and Director ElectionsNovember 15, 2024 | markets.businessinsider.com3 Growth Stocks Under $10 That Analysts Predict Will SkyrocketNovember 15, 2024 | stocknews.comThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.November 21, 2024 | Crypto 101 Media (Ad)Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 77% over the last three yearsOctober 29, 2024 | finance.yahoo.comAngioDynamics (ANGO) Stock Dips Amidst Financial Performance ReviewOctober 25, 2024 | gurufocus.comAngioDynamics and UCLH launch study of ‘long term effects’ of NanoKnife SystemOctober 24, 2024 | markets.businessinsider.comAngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call TranscriptOctober 5, 2024 | seekingalpha.comAngioDynamics (ANGO) Gets a Buy from H.C. WainwrightOctober 5, 2024 | markets.businessinsider.comSee More Headlines ANGO Stock Analysis - Frequently Asked Questions How have ANGO shares performed this year? AngioDynamics' stock was trading at $7.84 at the start of the year. Since then, ANGO stock has decreased by 14.0% and is now trading at $6.74. View the best growth stocks for 2024 here. How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings results on Thursday, October, 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics's revenue for the quarter was down 14.2% on a year-over-year basis. Does AngioDynamics have any subsidiaries? AngioDynamics subsidiaries include Eximo Medical Ltd., RadiaDyne LLC, Clinical Devices, Vortex Medical, Navilyst Medical Inc., FlowMedica, Oncovionic, and more. Who are AngioDynamics' major shareholders? AngioDynamics' top institutional investors include Systematic Financial Management LP (5.93%), Royce & Associates LP (2.43%), Geode Capital Management LLC (2.36%) and Segall Bryant & Hamill LLC (2.24%). Insiders that own company stock include James C Clemmer, James C Clemmer, Stephen A Trowbridge, Wesley Johnson, Warren Nighan Jr and Dave Helsel. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AngioDynamics investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings10/03/2024Today11/20/2024Next Earnings (Estimated)1/03/2025Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ANGO CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees748Year Founded1988Price Target and Rating Average Stock Price Target$12.00 High Stock Price Target$14.00 Low Stock Price Target$10.00 Potential Upside/Downside+78.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,350,000.00 Net Margins-83.95% Pretax Margin-81.70% Return on Equity-5.86% Return on Assets-4.17% Debt Debt-to-Equity RatioN/A Current Ratio2.25 Quick Ratio1.41 Sales & Book Value Annual Sales$303.91 million Price / Sales0.90 Cash Flow$4.24 per share Price / Cash Flow1.59 Book Value$5.13 per share Price / Book1.31Miscellaneous Outstanding Shares40,630,000Free Float38,440,000Market Cap$273.85 million OptionableOptionable Beta0.67 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:ANGO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AngioDynamics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.